Spyre Therapeutics, Inc. financial data

Symbol
SYRE on Nasdaq
Location
Waltham, MA
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 19 Feb 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 924% % -16%
Debt-to-equity 13% % -44%
Return On Equity -29% % 51%
Return On Assets -26% % 39%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 78,540,164 shares
Common Stock, Shares, Outstanding 78,189,811 shares 30%
Entity Public Float $1,100,000,000 USD 0%
Common Stock, Value, Issued $15,000 USD 15%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $0 USD -100%
General and Administrative Expense $47,909,000 USD 4.7%
Operating Income (Loss) $209,562,000 USD -0.48%
Nonoperating Income (Expense) $54,344,000 USD 8972%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $155,218,000 USD 25%
Income Tax Expense (Benefit) $15,000 USD -129%
Net Income (Loss) Attributable to Parent $155,203,000 USD 25%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $85,721,000 USD -4.1%
Cash, Cash Equivalents, and Short-term Investments $756,500,000 USD 25%
Assets, Current $777,781,000 USD 28%
Other Assets, Noncurrent $0 USD -100%
Assets $777,781,000 USD 28%
Liabilities, Current $58,685,000 USD 8.6%
Liabilities $62,545,000 USD -31%
Accumulated Other Comprehensive Income (Loss), Net of Tax $869,000 USD 383%
Retained Earnings (Accumulated Deficit) $1,127,635,000 USD -16%
Stockholders' Equity Attributable to Parent $715,236,000 USD 38%
Liabilities and Equity $777,781,000 USD 28%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $40,994,000 USD -44%
Net Cash Provided by (Used in) Financing Activities $125,000 USD -100%
Net Cash Provided by (Used in) Investing Activities $61,000 USD 100%
Common Stock, Shares Authorized 400,000,000 shares 0%
Common Stock, Shares, Issued 78,189,811 shares 30%
Common Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $40,930,000 USD -206%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $85,721,000 USD -4.1%
Deferred Tax Assets, Valuation Allowance $201,345,000 USD 24%
Deferred Tax Assets, Gross $201,528,000 USD 24%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $154,514,000 USD 26%
Deferred Tax Assets, Operating Loss Carryforwards $118,511,000 USD 36%
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Share-based Payment Arrangement, Expense $9,566,000 USD -27%
Preferred Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%